- Home
- ONCY vs SGMT Comparison
ONCY vs SGMT Comparison
Compare ONCY & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONCY
- SGMT
- Stock Information
- Founded
- ONCY 1998
- SGMT 2006
- Country
- ONCY Canada
- SGMT United States
- Employees
- ONCY N/A
- SGMT N/A
- Industry
- ONCY Pharmaceuticals and Biotechnology
- SGMT
- Sector
- ONCY Health Care
- SGMT
- Exchange
- ONCY Nasdaq
- SGMT Nasdaq
- Market Cap
- ONCY 86.1M
- SGMT 93.7M
- IPO Year
- ONCY 1999
- SGMT 2023
- Fundamental
- Price
- ONCY $0.98
- SGMT $4.73
- Analyst Decision
- ONCY Strong Buy
- SGMT Strong Buy
- Analyst Count
- ONCY 2
- SGMT 5
- Target Price
- ONCY $4.00
- SGMT $21.60
- AVG Volume (30 Days)
- ONCY 386.7K
- SGMT 792.4K
- Earning Date
- ONCY 11-12-2024
- SGMT 11-13-2024
- Dividend Yield
- ONCY N/A
- SGMT N/A
- EPS Growth
- ONCY N/A
- SGMT N/A
- EPS
- ONCY N/A
- SGMT N/A
- Revenue
- ONCY N/A
- SGMT N/A
- Revenue This Year
- ONCY N/A
- SGMT N/A
- Revenue Next Year
- ONCY N/A
- SGMT N/A
- P/E Ratio
- ONCY N/A
- SGMT N/A
- Revenue Growth
- ONCY N/A
- SGMT N/A
- 52 Week Low
- ONCY $0.84
- SGMT $2.31
- 52 Week High
- ONCY $1.75
- SGMT $20.71
- Technical
- Relative Strength Index (RSI)
- ONCY 36.89
- SGMT 41.81
- Support Level
- ONCY $1.01
- SGMT $5.61
- Resistance Level
- ONCY $1.15
- SGMT $6.40
- Average True Range (ATR)
- ONCY 0.06
- SGMT 0.53
- MACD
- ONCY -0.03
- SGMT -0.16
- Stochastic Oscillator
- ONCY 3.14
- SGMT 8.24
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).